What's New

Medical News
& Alerts

Conferences
& Meetings


Other Medical
Resources

Employment
Opportunities

Partnering
Opportunities

Search results for: Alexion
96%DGNews: MP4 Apogen Treatment For Multiple Sclerosis Reverses Paralysis
96%DGNews: C5 Inhibitor Reported To Block Apoptosis During Myocardial Infarction
96%DGNews: Alexion C5 Inhibitor Protects Blood Vessel Cells From Damage
93%DGNews: ACR: Phase II Drug Reduces Signs And Symptoms Of RA
91%DGNews: New Drug May Be Effective Treatment For MS
90%DGNews: FDA Grants Priority Review for Soliris(TM) (Eculizumab) BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria
87%DGNews: C5 Inhibitor Shows Biological Efficacy In Heart Surgery Patients
84%DGNews: AHA: Pexelizumab Reduces Death/Myocardial Infarction in Some Cardiopulmonary Bypass Patients
78%DGNews: Pulmonary Hypertension May Indicate Hemoglobinuria: Presented at ASH
78%DGNews: AHA: Pexelizumab Reduces Early and Late Events Following Coronary Artery Bypass Grafting
77%DGNews: Eculizumab Approved in Australia for Paroxysmal Nocturnal Haemoglobinuria
77%DGNews: Eculizumab Effective in Paroxysmal Nocturnal Haemoglobinuria: Presented at EHA
77%DGNews: Eculizumab Does Not Increase Risk of Leukaemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders: Presented at ASCO
75%DGNews: Eculizumab Approved in Canada for Paroxysmal Nocturnal Haemoglobinuria (PNH)
75%DGNews: Peg-Intron (Peginterferon Alfa-2b) As Safe As Intron A (Interferon Alfa-2b) In Hepatitis C Therapy
74%DGNews: FDA Approves First-of-its-Kind Drug to Treat Rare Blood Disorder
74%DGNews: Medication Does Not Appear to Offer Benefit for Certain Heart Attack Patients Undergoing Angioplasty or Stent Procedure
69%DGNews: Phase 3 Trial Looks at Safety and Efficacy of Eculizumab in Paroxysmal Nocturnal Haemoglobinuria: Presented at EHA
Enter keywords you wish to find information about:

Search for documents that contain:
any of these words.
this exact phrase.
all of these words.

 

 

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.

All contents Copyright (c) 1998 PSL Consulting Group Inc.
all rights reserved.